Robert Israel, MD

Title(s)Professor of Obstetrics & Gynecology
SchoolKeck School of Medicine of Usc
AddressIRD 501 2020 Zonal
Off Campus
Los Angeles CA 90033
Phone+1 626 808 5261
vCardDownload vCard
    Other Positions
    Title(s)Director of Gynecology Clinic Projects


    Collapse Overview 
    Collapse Overview
    Robert Israel, M.D., graduated with a BA in English and Anthropology from Harvard College, an MD from the University of Pennsylvania School of Medicine, and a residency in Obstetrics and Gynecology at The Johns Hopkins Hospital. He completed a post-residency, two-year obligation to the US Navy in the Department of Obstetrics and Gynecology at Balboa Naval Hospital in San Diego, California, where he established the first Infertility Clinic. He joined the new, full-time Department of Obstetrics and Gynecology at the University of Southern California (USC) School of Medicine in late 1969, and has remained a faculty member at that institution ever since, achieving professorial level. He has been a member of the department’s Executive Committee, since its inception in 1970. For over 25 years, he was the director of the department’s required medical student rotation. He chaired the division of gynecology at two different times for over 10 years. From 2005 -2007, he was the first director of development for the department. During that time period, he initiated two endowed department chairs and helped convert the department’s former resident organization into a significant alumni association. Presently, he is the chair of quality improvement for the department and director of the women’s health clinics. Nationally, he belongs to the Pacific Coast Reproductive Society and was its President in 1980, the American Society of Reproductive Medicine, the American College of Obstetricians and Gynecologists, and the Pacific Coast Obstetrical and Gynecological Society, having been its President in 2002 and, presently, the Chair of the Society’s Industry Liaison Committee. He has authored multiple, peer-reviewed publications, as well as book chapters. His medical interests include endometriosis, reproductive problems, myomata uteri, sterilization, intrauterine adhesions, and uterine congenital anomalies. Dr. Israel’s outside interests include the completion of ten marathons and classical theater, epitomized by his third appointment to the Board of Directors of A Noise Within, the classical repertory theater in the Los Angeles area.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients with Advanced Illness. J Pain Res. 2023; 16:3529-3543. Mehta N, Slatkin NE, Israel RJ, Stambler N, Shah ED. PMID: 37881233; PMCID: PMC10595216.
      View in: PubMed   Mentions:
    2. Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose. J Pain Res. 2023; 16:2595-2607. Chamberlain BH, Rhiner M, Slatkin NE, Stambler N, Israel RJ. PMID: 37533563; PMCID: PMC10391063.
      View in: PubMed   Mentions: Translation:CTClinical Trials
    3. Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis. Pain Med. 2023 03 01; 24(3):341-350. Webster LR, Brenner D, Israel RJ, Stambler N, Slatkin NE. PMID: 36102822; PMCID: PMC9977130.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    4. Cumulative Laxation Response with Methylnaltrexone: Implications for Hospitalized Patients with Advanced Illness and Opioid-Induced Constipation. Curr Ther Res Clin Exp. 2023; 98:100694. Farchadi D, Slatkin NE, Stambler N, Israel RJ, Matus M. PMID: 36875317; PMCID: PMC9981808.
      View in: PubMed   Mentions:    Fields:    
    5. A Randomized, Double-Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers. Clin Pharmacol Drug Dev. 2023 03; 12(3):236-248. Lee J, Lester R, O'Reilly T, Lowe ER, Slatkin NE, Franklin H, Israel RJ. PMID: 36708138.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. A randomized, placebo-controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin. Clin Transl Sci. 2022 09; 15(9):2159-2171. Couroux P, Brkovic A, Vittitow JL, Israel RJ, Pamidi C, Patel J, Barakat M. PMID: 35677972; PMCID: PMC9468560.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    7. First-Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis. J Emerg Med. 2022 02; 62(2):231-239. Peacock WF, Slatkin NE, Israel RJ, Stambler N. PMID: 34893381.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. P029 Pharmacokinetic/Pharmacodynamic Analysis of Amiselimod, a Selective Sphingosine 1-Phosphate Receptor Modulator, in Healthy Subjects: Results From a Phase 1 Study. Am J Gastroenterol. 2021 Dec 01; 116(Suppl 1):S7. Lee J, Lester R, O'Reilly T, Lowe E, Slatkin N, Franklin H, Israel R. PMID: 37461948.
      View in: PubMed   Mentions: 1     Fields:    
    9. Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation: a post hoc pooled analysis of two clinical trials. F1000Res. 2021; 10:891. Mehta N, Slatkin NE, Israel RJ, Stambler N. PMID: 34631030; PMCID: PMC8485099.
      View in: PubMed   Mentions: 1     Fields:    
    10. Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Cancer versus Noncancer Patients: An Analysis of Efficacy and Safety Variables from Two Studies. J Pain Res. 2021; 14:2687-2697. Chamberlain BH, Rhiner M, Slatkin NE, Stambler N, Israel RJ. PMID: 34512008; PMCID: PMC8420564.
      View in: PubMed   Mentions: 4  
    11. The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies. Support Care Cancer. 2021 Sep; 29(9):5209-5218. Brenner DM, Slatkin NE, Stambler N, Israel RJ, Coluzzi PH. PMID: 33629189; PMCID: PMC8295095.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    12. Subcutaneous methylnaltrexone for opioid-induced constipation in advanced-illness patients with or without active cancer. Pain Manag. 2020 Mar; 10(2):73-84. Chamberlain BH, Rhiner M, Slatkin NE, Stambler N, Israel RJ. PMID: 31951150.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    13. Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. J Pain Res. 2019; 12:139-150. Rauck RL, Slatkin NE, Stambler N, Israel RJ. PMID: 30613162; PMCID: PMC6307492.
      View in: PubMed   Mentions: 3  
    14. Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain. Pain Pract. 2017 07; 17(6):820-828. Rauck R, Slatkin NE, Stambler N, Harper JR, Israel RJ. PMID: 27860208.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    15. Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension. J Palliat Med. 2015 Jul; 18(7):593-600. Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C, Forbes WP. PMID: 25973526; PMCID: PMC4492709.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    16. Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials. J Pain Symptom Manage. 2011 Nov; 42(5):754-60. Slatkin NE, Lynn R, Su C, Wang W, Israel RJ. PMID: 22045373.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    17. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009 Jan-Feb; 7(1):39-46. Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, Zhukovsky DS, Stephenson R, Portenoy R, Stambler N, Israel R. PMID: 19278178.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    18. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008 May 29; 358(22):2332-43. Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, Stambler N, Kremer AB, Israel RJ. PMID: 18509120.
      View in: PubMed   Mentions: 132     Fields:    Translation:HumansCTClinical Trials
    19. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008 May; 35(5):458-68. Portenoy RK, Thomas J, Moehl Boatwright ML, Tran D, Galasso FL, Stambler N, Von Gunten CF, Israel RJ. PMID: 18440447.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    20. The relationship between physicians and industry: Faustian or symbiotic? Am J Obstet Gynecol. 2003 Jun; 188(6):1530-40. Israel R. PMID: 12824990.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Evaluation of a large cohort of men presenting for a screening semen analysis. Fertil Steril. 2000 Mar; 73(3):595-7. Acacio BD, Gottfried T, Israel R, Sokol RZ. PMID: 10689019.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    Robert's Networks
    Concepts (65)
    Derived automatically from this person's publications.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _